Definitive Healthcare (DH) has outlined a strategic vision targeting $220 million to $222 million in total revenue for 2026, a forecast underpinned by plans for the general availability of its “Turbo” product before the close of the current year. This forward-looking guidance emerges as the healthcare data analytics firm navigates a challenging quarter.
Q2 2026 Financial Overview
For the second quarter of 2026, Definitive Healthcare reported total revenue of $55.2 million, marking a 9% decrease year-over-year. Adjusted EBITDA for the period stood at $14.6 million, achieving a margin of 26%. CEO Kevin Coop directly addressed these figures, stating, “Total revenue was $55.2 million, down 9% year-over-year. Adjusted EBITDA was $14.6 million, representing a margin of 26%.”
Strategic Product Launch
The company’s ambitious 2026 revenue target is closely tied to the anticipated launch of its Turbo offering. Management’s intention to make Turbo generally available before year-end signals a key strategic initiative aimed at driving future growth and market penetration. While specific details on Turbo’s capabilities were not elaborated in the available insights, its planned rollout is a central component of Definitive Healthcare’s path to its multi-million dollar revenue goal.
Definitive Healthcare’s management appears focused on leveraging new product introductions, such as Turbo, to reverse recent revenue trends and achieve its stated financial objectives for 2026, balancing current performance with future growth catalysts.
